
Almirall to focus on respiratory and skin diseases
Catalan Economy
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
Related News and Success stories.
-
29 Sep 2025
Lidl launches €140M logistics platform in Barcelona, its biggest in Spain
-
22 Sep 2025
HIPRA opens new €500M Biotech campus in Catalonia, strengthening Europe’s Life Sciences hub
-
18 Sep 2025
DHL Express inaugurates new €80M international hub in Barcelona
-
15 Sep 2025
Trace ID opens new 2,000 m2 chip welding plant in Barcelona, a European first